journal article·2024-08Open access

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine-like functions for nanoparticle release

Marianna TP Favaro, Hèctor López-Laguna, Eric Voltà-Durán, Lorena Alba-Castellon, Julieta M. Sánchez, Isolda Casanova, Ugutz Unzueta, Ramón Mangues, Antonio Villaverde, Esther Vázquez

Abstract

The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. D. Mishra, K. Glover, S. Gade, R. Sonawane, T. Raghu Raj Singh, Safety, biodegradability, and biocompatibility considerations of long-acting drug delivery systems, in: Long-Acting Drug Delivery Systems: Pharmaceutical, Clinical, and Regulatory Aspects, 2021. 10.1016/B978-0-12-821749-8.00008-2.10.1016/B978-0-12-821749-8.00008-2 ↗
2. Recent advances for improving functionality, biocompatibility, and longevity of implantable medical devices and deliverable drug delivery systems
3. Biocompatibility issues of implantable drug delivery systems10.1023/A:1016012520276 ↗
4. Biocompatibility and drug delivery systems
5. A brief review on sustained release matrix type drug delivery system
6. Sustained release drug delivery system with the role of natural polymers: a review
7. Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques10.3390/pharmaceutics12121188 ↗
8. A review of biodegradable natural polymer-based nanoparticles for drug delivery applications10.3390/nano10101970 ↗
9. Polymers for drug delivery systems10.1146/annurev-chembioeng-073009-100847 ↗
10. Designing hydrogels for controlled drug delivery10.1038/natrevmats.2016.71 ↗
11. Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: inserts, patches, wafers, and implants10.1016/j.addr.2021.113957 ↗
12. Drug delivery systems: past, present and future
13. Functional amyloids are the rule rather than the exception in cellular biology10.3390/microorganisms8121951 ↗
14. Two decades of studying functional amyloids in microorganisms10.1016/j.tim.2020.09.005 ↗
15. The role of functional amyloids in bacterial virulence10.1016/j.jmb.2018.07.010 ↗
16. Functional mammalian amyloids and amyloid-like proteins10.3390/life10090156 ↗
17. Functional amyloids of eukaryotes: criteria, classification, and biological significance10.1007/s00294-020-01079-7 ↗
18. M. Spiess, N. Beuret, C. Prescianotto Baschong, J. Rutishauser, Amyloid-like aggregation of provasopressin, in: Vitam Horm, 2020. https://doi.org/10.1016/bs.vh.2019.08.014.10.1016/bs.vh.2019.08.014 ↗
19. Reversible, functional amyloids: towards an understanding of their regulation in yeast and humans10.1080/15384101.2018.1480220 ↗
20. Diversity, biogenesis and function of microbial amyloids
21. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules10.1126/science.1173155 ↗
22. The three-dimensional structure of human β-endorphin amyloid fibrils10.1038/s41594-020-00515-z ↗
23. Toward a comprehension of functional aggregation into amyloids in pituitary secretory granules
24. Immunocytochemical and immuno-electron-microscopical study of growth hormone cells in male and female rats of various ages10.1007/BF00318183 ↗
25. Resistance exercise stress: theoretical mechanisms for growth hormone processing and release from the anterior pituitary somatotroph10.1007/s00421-023-05263-8 ↗
26. Prolactin and growth hormone aggregates in secretory granules: the need to understand the structure of the aggregate
27. Mechanisms for storage of prolactin and growth hormone in secretory granules10.1016/S1096-7192(02)00011-2 ↗
28. Amyloid formation of growth hormone in presence of zinc: relevance to its storage in secretory granules10.1038/srep23370 ↗
29. D. Chatterjee, R.S. Jacob, S. Ray, A. Navalkar, N. Singh, S. Sengupta, L. Gadhe, P. Kadu, D. Datta, A. Paul, A. Sakunthala, S. Mehra, C. Pindi, S. Kumar, P.S. Singru, S. Senapati, S.K. Maji, Co-aggregation and secondary nucleation in the life cycle of human prolactin/galanin functional amyloids, Elife 11 (2022). 10.7554/eLife.73835.10.7554/eLife.73835 ↗
30. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy10.1615/CritRevTherDrugCarrierSyst.v16.i6.20 ↗
31. Formulation design: new drugs from old10.1016/j.ddstr.2004.11.020 ↗
32. Pharmacodynamic aspects of sustained release preparations10.1016/S0169-409X(98)00027-1 ↗
33. Artificial inclusion bodies for clinical development10.1002/advs.201902420 ↗
34. Structural stabilization of clinically oriented oligomeric proteins during their transit through synthetic secretory amyloids10.1002/advs.202309427 ↗
35. Biofabrication of functional protein nanoparticles through simple His-tag engineering10.1021/acssuschemeng.1c04256 ↗
36. Protein features instruct the secretion dynamics from metal-supported synthetic amyloids10.1016/j.ijbiomac.2023.126164 ↗
37. Time-prolonged release of tumor-targeted protein–MMAE nanoconjugates from implantable hybrid materials10.3390/pharmaceutics14010192 ↗
38. P. Álamo, E. Parladé, H. López-Laguna, E. Voltà-Durán, U. Unzueta, E. Vazquez, R. Mangues, A. Villaverde, Ion-dependent slow protein release from in vivo disintegrating micro-granules, 28 (2021) 2383–2391. 10.1080/10717544.2021.1998249.10.1080/10717544.2021.1998249 ↗
39. Nanoparticle-based secretory granules induce a specific and long-lasting immune response through prolonged antigen release10.3390/nano14050435 ↗
40. N. Serna, O. Cano-Garrido, J.M. Sánchez, A. Sánchez-Chardi, L. Sánchez-García, H. López-Laguna, E. Fernández, E. Vázquez, A. Villaverde, Release of functional fibroblast growth factor-2 from artificial inclusion bodies, (2020). 10.1016/j.jconrel.2020.08.007.10.1016/j.jconrel.2020.08.007 ↗
41. Efficient delivery of antimicrobial peptides in an innovative, slow-release pharmacological formulation10.3390/pharmaceutics15112632 ↗
42. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients10.1517/17425240903199143 ↗
43. Chemical and physical instabilities in manufacturing and storage of therapeutic proteins10.1016/j.copbio.2019.01.014 ↗
44. Challenges for the pharmaceutical technical development of protein coformulations10.1111/jphp.12731 ↗
45. Physicochemical factors of bioprocessing impact the stability of therapeutic proteins10.1016/j.biotechadv.2022.107909 ↗
46. Instability challenges and stabilization strategies of pharmaceutical proteins10.3390/pharmaceutics14112533 ↗
47. Excipients in freeze-dried biopharmaceuticals: contributions toward formulation stability and lyophilisation cycle optimisation10.1016/j.ijpharm.2020.119029 ↗
48. Lyophilisation of protein-based drugs
49. Technological approaches to improving the process lyophilization of protein and peptide drugs
50. A review on parenteral delivery of peptides and proteins10.1080/03639045.2019.1628770 ↗
51. Different structural conformers of monomeric α-synuclein identified after lyophilizing and freezing10.1021/acs.analchem.8b01264 ↗
52. Simple, reliable protocol for high-yield solubilization of seedless amyloid-β monomer10.1021/acschemneuro.2c00411 ↗
53. Preparation of amyloid β-protein for structural and functional studies
54. C. Wu, S. Shamblin, D. Varshney, E. Shalaev, Advance understanding of buffer behavior during lyophilization, in: Lyophilized Biologics and Vaccines, Springer New York, New York, NY, 2015: pp. 25–41. https://doi.org/10.1007/978-1-4939-2383-0_3.10.1007/978-1-4939-2383-0_3 ↗
55. Role of buffers in protein formulations10.1016/j.xphs.2016.11.014 ↗
56. Investigating freezing-induced acidity changes in citrate buffers10.1016/j.ijpharm.2023.123211 ↗
57. Variation of citrate to metal cation ratio for dense and phase pure BaZrO 3 via autocombustion synthesis10.1111/jace.18477 ↗
58. The effect of chelating agents including potassium tartrate and citrate on the maximum reduction of lead and cadmium during soaking and cooking from some different varieties of rice available in Iran10.1002/fsn3.2473 ↗
59. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the zucker diabetic rat
60. Citrate is an endogenous inhibitor of snake venom enzymes by metal-ion chelation10.1016/0041-0101(92)90440-G ↗
61. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors10.1016/j.apsb.2021.09.030 ↗
62. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
63. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T14010.1006/bbrc.1998.9871 ↗
64. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection10.1084/jem.186.8.1389 ↗
65. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection10.1128/JVI.76.2.933.2002 ↗
66. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles
67. CXCR4 and cancer: review Article
68. CXCR4-directed theranostics in oncology and inflammation10.1007/s12149-018-1290-8 ↗
69. CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer10.1007/s13277-013-1545-x ↗
70. CXCR4 over-expression and survival in cancer: a system review and meta-analysis
71. T22-PE24-H6 nanotoxin selectively kills CXCR4-high expressing AML patient cells in vitro and potently blocks dissemination in vivo
72. A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy10.1039/D2BM02026B ↗
73. Self-assembled multivalency: dynamic ligand arrays for high-affinity binding10.1002/anie.201200076 ↗
74. Nanoparticle multivalency directed shifting of cellular uptake mechanism
75. Lyophilization and development of solid protein pharmaceuticals10.1016/S0378-5173(00)00423-3 ↗
76. The Preservation of lyophilized human growth hormone activity: how do buffers and sugars interact?10.1007/s11095-018-2410-9 ↗
77. Combination of hydrophobically modified γ-poly(glutamic acid) and trehalose achieving high cryosurvival of RBCs10.1007/s11431-020-1549-2 ↗
78. Poly(trehalose methacrylate) as an excipient for insulin stabilization: mechanism and safety10.1021/acsami.2c09301 ↗
79. Towards protein-based viral mimetics for cancer therapies
80. AMD3100/CXCR4 inhibitor10.3389/fimmu.2015.00276 ↗
81. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR410.1016/S0014-5793(02)03143-5 ↗
82. The CXCR4 antagonist AMD3100 has dual effects on survival and proliferation of myeloma cells in vitro10.4143/crt.2010.42.4.225 ↗
83. Artificial peptide-controlled protein release of Zn2+-triggered, self-assembled histidine-tagged protein microparticle10.1016/j.colsurfb.2019.110644 ↗
84. Zinc-assisted microscale granules made of the SARS-CoV-2 spike protein trigger neutralizing, antivirus antibody responses10.1021/acsmaterialslett.3c01643 ↗
85. Overview on controlled release dosage forms
86. Formulation approaches for sustained release dosage forms: a review
87. The stability of transition-metal complexes10.1039/jr9530003192 ↗
88. C. Wu, S. Shamblin, D. Varshney, E. Shalaev, Advance understanding of buffer behavior during lyophilization, in: Lyophilized Biologics and Vaccines, 2015. 10.1007/978-1-4939-2383-0_3.10.1007/978-1-4939-2383-0_3 ↗
89. The effect of buffers on protein conformational stability
90. Citrate conformation and chelation: enzymatic implications10.1021/ar50154a002 ↗
91. Preparation and characterization of nickel ferrite nano particles by co-precipitation method with citrate as chelating agent
92. Instability of therapeutic proteins — An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins10.1016/j.ijbiomac.2020.11.188 ↗
93. Development of stable lyophilized protein drug products10.2174/138920112799361990 ↗
94. A. Alexeenko, E. Topp, Future directions: lyophilization technology roadmap to 2025 and beyond, in: Drying Technologies for Biotechnology and Pharmaceutical Applications, 2020. 10.1002/9783527802104.ch15.10.1002/9783527802104.ch15 ↗
95. Hybrid micro-/nanoprotein platform provides endocrine-like and extracellular matrix-like cell delivery of growth factors10.1021/acsami.4c01210 ↗
96. Rational design of stable lyophilized protein formulations: theory and practice
97. Divalent cations: a molecular glue for protein materials trends in biochemical sciences an official publication of the international union of biochemistry and molecul ar biology
98. Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides10.1007/s40843-019-1231-y ↗
99. Trends in peptide drug discovery10.1038/s41573-020-00135-8 ↗
100. Peptide-based drug discovery: current status and recent advances10.1016/j.drudis.2022.103464 ↗